DiaMedica Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
DiaMedica Therapeutics (DMAC) reported a net loss of $11.3 million ($0.21 per share) for the third quarter of 2026, compared to an $8.6 million loss in the prior-year period. The increase in losses was driven primarily by higher R&D expenses, which rose to $9.2 million due to clinical team expansion and global activities related to the ReMEDy2 program. As of September 30, 2026, the company held $34.9 million in cash and short-term investments, providing a projected runway into the fourth quarter of 2027. On the clinical front, the company reached a significant milestone in October 2026 by hitting the 200-participant threshold for its AIS interim analysis, triggering an independent data review. Management also provided updates on its FGR and preeclampsia studies, noting enrollment progress and upcoming dose-finding phases. While clinical activities are accelerating, CEO Rick Pauls noted potential risks regarding site administration and process constraints that could impact enrollment timelines into early 2027.
Tickers: $DMAC
Topics: cash runway clinical trials earnings report R&D spending